1. Prospective Study in Children with Complicated Urinary Tract Infection Treated with Autologous Bacterial Lysates
- Author
-
Ulises Hernández-Chiñas, María E. Chávez-Berrocal, Ricardo E. Ahumada-Cota, Armando Navarro-Ocaña, Luz M. Rocha-Ramírez, Yolanda Pérez-del Mazo, Maribel Alvarado-Cabello, Gabriel Pérez-Soto, Luis A. León-Alamilla, Salvador E. Acevedo-Monroy, Diego Esquiliano, Atlántida M. Raya-Rivera, and Carlos A. Eslava
- Subjects
UTI ,Escherichia coli ,UPEC ,autologous bacterial lysates ,autovaccine ,Biology (General) ,QH301-705.5 - Abstract
Antimicrobial bacteria resistance is an important problem in children with recurrent urinary tract infections (rUTI), thus it is crucial to search for alternative therapies. Autologous bacterial lysates (ABL) may be a potential treatment for rUTI. Twenty-seven children with rUTI were evaluated for one year, urine and stool cultures were performed, 10 colonies of each culture were selected and those identified as Escherichia coli were characterized by serology. For patients who presented ≥105 UFC/mL, an ABL was manufactured and administered orally (1 mL/day) for a month. Twelve children were monitored for ≥1-year, 218 urine and 11 stool samples were analyzed. E. coli (80.5%) was the main bacteria isolated from urine and feces (72%). E. coli of classical urinary serotypes (UPEC), O25:H4, O75:HNM, and O9:HNM were identified in patients with persistent urinary infection (pUTI). In 54% of patients treated with ABL, the absence of bacteria was observed in urine samples after 3 months of treatment, 42% of these remained without UTI between 10–12 months. It was observed that the use of ABL controlled the infection for almost 1 year in more than 60% of the children. We consider it necessary to develop a polyvalent immunogen for the treatment and control of rUTI.
- Published
- 2021
- Full Text
- View/download PDF